Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Sanrio Shares Plunge as Q1 Profit Miss Overshadows Strong Sales 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Oil Prices Fall as U.S. Crude Inventories Surge and Hormuz Tensions Persist 
France Inflation Rises 2.4% in July as Consumer Prices Increase 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
Asian Currencies Steady as Dollar Holds Firm After U.S. Inflation Data 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Asian Currencies Edge Higher as Soft US Inflation Weighs on Dollar 
Gold Prices Retreat From Two-Month High as Softer Inflation Eases Fed Rate Hike Bets 
Trump Imposes New US Tariffs on Drone Imports Over National Security Concerns 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Alphabet’s SpaceX Investment Soars 100-Fold to $94 Billion 
Add as a preferred source on Google
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
